1.Expression of PRAME gene in adult acute leukemia and its significance in prognosis.
Pei-Yi ZHOU ; Wei-Jia LI ; Cai-Xia WEI ; Zhi ZHOU
Journal of Experimental Hematology 2007;15(6):1177-1181
The study was aimed to investigate the expression of preferentially expressed antigen of melanoma (PRAME) gene in adult acute leukemia and its clinical significance. The expression of the PRAME gene of bone marrow was measured by reverse transcriptase polymerase chain reaction (RT-PCR) in 73 adult newly diagnosed acute leukemia patients, 3 relapsed patients, 7 patients with idiopathic thrombocytopenic purpura (ITP) and 8 healthy donors, as well as two AL cell-lines (K562 and U937). The results indicated that PRAME mRNA was expressed in 42.9% AML patients (n=24) and 20% ALL patients (n=4), also in two leukemia cell-lines K562 and U937, but not in eight health donors and seven ITP patients. PRAME expression not correlated to the white blood count, hemoglobin level, platelet count and the percentage of blasts at diagnosis, yet independent of age, sex, and FAB type. PRAME mRNA expression in complete remission group seems much higher than those in partial complete remission group and death group. The increased levels of expression could be found prior to the relapse in one patient being regularly monitored. PRAME gene was overexpressed in adult acute leukemia patients and leukemia cell-lines. It is concluded that the expression of PRAME is an indicator of favorable prognosis and can be a useful tool for monitoring minimal residual disease (MRD) in adult acute leukemia. Differential expression between adult acute leukemia patients and healthy volunteers suggests that the immunogenic antigens PRAME are potential candidates for immunotherapy in adult acute leukemia.
Acute Disease
;
Adolescent
;
Adult
;
Aged
;
Antigens, Neoplasm
;
metabolism
;
Female
;
Humans
;
Leukemia
;
genetics
;
metabolism
;
Leukemia, Myeloid, Acute
;
genetics
;
metabolism
;
Male
;
Middle Aged
;
Neoplasm, Residual
;
diagnosis
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
genetics
;
metabolism
;
Prognosis
;
RNA, Messenger
;
metabolism
;
Young Adult
2.Significance of id4 promoter methylation in monitoring AML patients with completely remission.
Yu ZHAO ; Quan-Shun WANG ; Hong-Hua LI ; Jian BO ; Li-Ping DOU ; Yu JING ; Shu-Hong WANG ; Li YU
Journal of Experimental Hematology 2008;16(3):476-478
The study was purposed to investigate the significance of id4 gene promoter methylation in monitoring AML patients with complete remission (CR). Methylation specific-PCR (MS-PCR) were used to detect the status of promoter methylation of id4 gene in bone marrow samples from AML patients with CR who had accepted induction with DA or IA and 4 to 5 consolidation chemotherapy with Ara-C. The results showed that in the all 32 patients, 15 were found to show id4 promoter methylation and 7 out of the 15 were found relapsed or tendency to relapse in the following-up period. While all the 17 patients with id4 unmethylation were still in their CR status in the same period. In conclusion, id4 promoter methylation might be a predictor for relapse of AML patients with CR in certain degree.
DNA Methylation
;
Humans
;
Inhibitor of Differentiation Proteins
;
genetics
;
Leukemia, Myeloid, Acute
;
genetics
;
metabolism
;
Neoplasm, Residual
;
diagnosis
;
genetics
;
Promoter Regions, Genetic
;
genetics
3.Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis.
Ya WANG ; Meng Yue HOU ; Yao FU ; Kui MENG ; Hong Yan WU ; Jin CHEN ; Yue Mei XU ; Jiong SHI ; Xiang Shan FAN
Chinese Journal of Pathology 2023;52(4):358-363
Objective: To investigate the expression of glycoprotein non metastatic melanoma protein B (GPNMB) in renal eosinophilic tumors and to compare the value of GPNMB with CK20, CK7 and CD117 in the differential diagnosis of renal eosinophilic tumors. Methods: Traditional renal tumor eosinophil subtypes, including 22 cases of renal clear cell carcinoma eosinophil subtype (e-ccRCC), 19 cases of renal papillary cell carcinoma eosinophil subtype (e-papRCC), 17 cases of renal chromophobe cell carcinoma eosinophil subtype (e-chRCC), 12 cases of renal oncocytoma (RO) and emerging renal tumor types with eosinophil characteristics [3 cases of eosinophilic solid cystic renal cell carcinoma (ESC RCC), 3 cases of renal low-grade eosinophil tumor (LOT), 4 cases of fumarate hydratase-deficient renal cell carcinoma (FH-dRCC) and 5 cases of renal epithelioid angiomyolipoma (E-AML)], were collected at the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2017 to March 2022. The expression of GPNMB, CK20, CK7 and CD117 was detected by immunohistochemistry and statistically analyzed. Results: GPNMB was expressed in all emerging renal tumor types with eosinophil characteristics (ESC RCC, LOT, FH-dRCC) and E-AML, while the expression rates in traditional renal eosinophil subtypes e-papRCC, e-chRCC, e-ccRCC and RO were very low or zero (1/19, 1/17, 0/22 and 0/12, respectively); the expression rate of CK7 in LOT (3/3), e-chRCC (15/17), e-ccRCC (4/22), e-papRCC (2/19), ESC RCC (0/3), RO (4/12), E-AML(1/5), and FH-dRCC (2/4) variedly; the expression of CK20 was different in ESC RCC (3/3), LOT(3/3), e-chRCC(1/17), RO(9/12), e-papRCC(4/19), FH-dRCC(1/4), e-ccRCC(0/22) and E-AML(0/5), and so did that of CD117 in e-ccRCC(2/22), e-papRCC(1/19), e-chRCC(16/17), RO(10/12), ESC RCC(0/3), LOT(1/3), E-AML(2/5) and FH-dRCC(1/4). GPNMB had 100% sensitivity and 97.1% specificity in distinguishing E-AML and emerging renal tumor types (such as ESC RCC, LOT, FH-dRCC) from traditional renal tumor types (such as e-ccRCC, e-papRCC, e-chRCC, RO),respectively. Compared with CK7, CK20 and CD117 antibodies, GPNMB was more effective in the differential diagnosis (P<0.05). Conclusion: As a new renal tumor marker, GPNMB can effectively distinguish E-AML and emerging renal tumor types with eosinophil characteristics such as ESC RCC, LOT, FH-dRCC from traditional renal tumor eosinophil subtypes such as e-ccRCC, e-papRCC, e-chRCC and RO, which is helpful for the differential diagnosis of renal eosinophilic tumors.
Humans
;
Kidney Neoplasms/pathology*
;
Carcinoma, Renal Cell/pathology*
;
Diagnosis, Differential
;
Angiomyolipoma/diagnosis*
;
Biomarkers, Tumor/metabolism*
;
Leukemia, Myeloid, Acute/diagnosis*
;
Membrane Glycoproteins
4.Expression of thioredoxin-2 for monitoring minimal residual disease in acute leukemia.
Qiong LUO ; Zhixin HUANG ; Liuping LUO ; Dingzhang XIAO
Journal of Central South University(Medical Sciences) 2013;38(4):383-387
OBJECTIVE:
To investigate the significance of human thioredoxin-2 (TRX-2) in monitoring minimal residual disease (MRD) in acute leukemia (AL).
METHODS:
We used real-time quantitative PCR to serially quantitize TRX-2 expression levels in the bone marrow of AL patients at diagnosis (n=68), at complete hematologic remission (CHR, n=57) and at relapse (n=25). Another 25 normal donors served as normal controls. The upper limit of the bone marrow at 91 was regarded as the reference. TRX-2 expression level at CHR with <5% blast cells in the bone marrow of relapse patients was analyzed and compared with MRD by flow cytometry.
RESULTS:
The TRX-2 levels between the CHR patients and newly diagnosed patients, and between the CHR patients and the relapse patients had significant difference. TRX-2 expression level of 21(21/25) relapse patients at CHR with <5% blast cells in the bone marrow was higher than the reference (>91). TRX-2 level was correlated to the expression level of MRD.
CONCLUSION
TRX-2 may be the marker for AL and used in MRD monitoring.
Case-Control Studies
;
Female
;
Humans
;
Leukemia, Myeloid, Acute
;
diagnosis
;
genetics
;
metabolism
;
Male
;
Neoplasm, Residual
;
diagnosis
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
diagnosis
;
genetics
;
metabolism
;
Real-Time Polymerase Chain Reaction
;
Thioredoxins
;
genetics
;
metabolism
5.Clinical Utility of Adenosine Deaminase Isoenzyme Determinations in Leukemia.
Dong Hoon SHIN ; Hyun Chan CHO ; Sung Ha KANG ; Il Gu PARK ; Kap Jun YOON
Korean Journal of Clinical Pathology 1999;19(2):181-189
BACKGROUND: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic deamination of adenosine or 2-deoxyadenosine to inosine or 2-deoxyinosine. Human ADA consists of three molecular forms: ADA1, ADA1+CP, and ADA2. The two ADA isoenzymes represent two different gene products and have different tissue distributions, and their concentrations in serum appear to reflect different pathological conditions or physiological responses. Elevation of serum ADA activity has been described especially in leukemia and lymphoma. The purpose of this study was to evaluate the clinical utility of ADA isoenzyme determination in the diagnosis of leukemia. METHODS: We studied the activity of serum ADA and its isoenzyme in 44 leukemic patients. The study population consisted of 17 patients with acute lymphoblastic leukemia (ALL), 23 with acute myeloid leukemia (AML), and 4 with chronic myelogenous leukemia (CML). ADA isoenzyme was measured by erythro-9- (2-hydroxy-3-nonyl) adenine [EHNA] inhibitory assay using the Hitachi 7170 autoanalyzer. RESULTS: The rates of abnormally high total ADA activity were 100% for ALL, 60.8% for AML, and 50% for CML. In isoenzyme pattern, there was a clear difference between ALL and AML. High level of ADA1 activity was found in patients with ALL (P <0.01). The ADA1/ADA2 ratio was significantly higher (P <0.001) in ALL than AML. There was a correlation between ADA1 and absolute number of peripheral blasts in AML (r=0.840). CONCLUSIONS: It is concluded that the measurement of ADA isoenzyme may be a useful biochemical marker for leukemic diagnosis.
Adenine
;
Adenosine Deaminase*
;
Adenosine*
;
Biomarkers
;
Deamination
;
Diagnosis
;
Humans
;
Inosine
;
Isoenzymes
;
Leukemia*
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
Leukemia, Myeloid, Acute
;
Lymphoma
;
Metabolism
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Tissue Distribution
6.Clinical analysis of acute myeloid leukemia with CBFB-MYH11-positive.
Ting-Ting CAO ; Min-Hang ZHOU ; Lei YUAN ; Qian WANG ; Li-Ping DOU ; Yuan-Yuan XU ; Nan WANG ; Li-Li WANG ; Li YU ; Yu JING
Journal of Experimental Hematology 2013;21(2):305-310
The study was aimed to investigate the clinical characteristics of acute myeloid leukemia (AML) with CBFB-MYH11 gene. The clinical data of 12 cases were analyzed retrospectively, including age, clinical characteristics, immunophenotype, treatment protocols and efficacy as well as the prognosis. The results indicated that 12 patients with CBFB-MYH11 were detected in 293 AML patients. The median age of the 12 patients was 32.5 (21 - 57) years old. According to French-American-British (FAB) classification, 66.7% (8/12) patients was diagnosed as M4Eo and 33.3% patients was diagnosed as M4. At new diagnosis, the median WBC count was 19.8×10(9)/L (2.46 - 164.30×10(9)/L). The WBC count > 100×10(9) was found in 16.7% patients (2/12). The complete remission (CR) rate after 1 and 2 cycles of induction chemotherapy were 83.3% and 16.7% respectively, so the total CR rate was 100%. Estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 80% and 83%, respectively. It is concluded that patients with CBFB-MYH11 are usually M4Eo and M4. Patients with this fusion gene are often associated with high frequency of CD33, CD34, CD117, HLA-DR, CD15, CD64 and CD14 expression. Patients with CBFB-MYH11 have a tendency of higher CR rate, longer RFS and OS.
Adult
;
Female
;
Humans
;
Immunophenotyping
;
Induction Chemotherapy
;
Leukemia, Myeloid, Acute
;
diagnosis
;
drug therapy
;
genetics
;
Male
;
Middle Aged
;
Oncogene Proteins, Fusion
;
genetics
;
metabolism
;
Prognosis
;
Retrospective Studies
;
Young Adult
7.A Case of Therapy-Related Acute Myeloid Leukemia With a Normal Karyotype After Sustained Molecular Complete Remission of Acute Promyelocytic Leukemia.
Sang Hyuk PARK ; Hyun Sook CHI ; Young Uk CHO ; Seongsoo JANG ; Chan Jeoung PARK ; Je Hwan LEE
Annals of Laboratory Medicine 2014;34(1):68-70
No abstract available.
Antineoplastic Agents/*adverse effects/*therapeutic use
;
Bone Marrow Cells/metabolism
;
Humans
;
Karyotyping
;
Leukemia, Myeloid, Acute/*chemically induced/*diagnosis/genetics
;
Leukemia, Promyelocytic, Acute/*drug therapy
;
Male
;
Middle Aged
;
Oncogene Proteins, Fusion/genetics
;
Remission Induction
;
Tretinoin/therapeutic use
8.Distribution of Antigenic Aberration in the Bone Marrow of Acute Leukemia in Complete Remission.
Soyoung SHIN ; Jimin KAHNG ; Myungshin KIM ; Jihyang LIM ; Younggoo KIM ; Kyungja HAN
The Korean Journal of Laboratory Medicine 2008;28(1):1-7
BACKGROUND: The aberrant, leukemia-associated antigen expression patterns allow us to discriminate leukemic blasts from normal precursor cells. Our major goal was to determine a guideline for the detection of minimal residual disease using CD20+/CD34+ and myeloid Ag+/CD19+ combination in the bone marrow of acute leukemia in complete remission (CR) after chemotherapy. METHODS: Bone marrow samples from 117 patients with acute leukemia in complete remission after chemotherapy and from 22 healthy controls were immunophenotyped by triple staining and measured by flow cytometry. RESULTS: The CD20+/CD34+ cells in the large lymphocyte gate (R1) ranged from 0% to 3.24% (0.8+/-0.82%, P=0.000) in CD20+/CD34+ B-lineage ALL CR (N=31), from 0.03% to 4.2% (0.7+/-0.83%, P=0.000) in CD20-/CD34- B-lineage ALL CR (N=66), from 0.1% to 0.96% (0.45+/-0.32%, P=0.016) in T-ALL CR (N=10), and from 0.02% to 0.48% (0.18+/-0.15%, P=0.776) in AML CR (N=10). The CD13,33+/CD19+ cells in R1 gate ranged from 0% to 2.69% (0.37+/-0.48%, P<0.001) in CD13,33+/CD19+ B-lineage ALL CR (N=31), from 0% to 1.8% (0.31+/-0.28%, P<0.001) in CD13,33-/CD19+B-lineage ALL CR (N=65), from 0.02% to 0.64% (0.29+/-0.22%, P=0.071) in T-ALL CR (N=9), and from 0% to 0.17% (0.07+/-0.09%, P=0.341) in AML CR (N=3). CONCLUSIONS: Using an immunophenotypic method for the detection of early relapse or minimal residual disease of B-lineage ALL bone marrow in CR after chemotherapy, different cutoff values should be applied according to antigen combination and gating. When the proportion of aberrant antigen combination was less than 5% in large lymphocyte gate, the results should be interpreted with caution.
Acute Disease
;
Antigens, CD/*metabolism
;
Antigens, CD19/metabolism
;
Antigens, CD20/metabolism
;
Antigens, CD34/metabolism
;
Antigens, Differentiation, Myelomonocytic/analysis/metabolism
;
Bone Marrow Cells/*classification/metabolism
;
Flow Cytometry
;
Hematopoietic Stem Cells/classification/metabolism
;
Humans
;
Immunophenotyping
;
Leukemia/*diagnosis/drug therapy
;
Leukemia, Myeloid, Acute/diagnosis/drug therapy
;
Neoplasm, Residual
;
Remission Induction
;
Tumor Markers, Biological/immunology
9.PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease.
Ya-zhen QIN ; Jin-lan LI ; Hong-hu ZHU ; Ling-di LI ; Yan CHANG ; Le HAO ; Ya-zhe WANG ; Bin JIANG ; Xi-jing LU ; Yan-rong LIU ; Xiao-jun HUANG ; Shan-shan CHEN
Chinese Journal of Hematology 2008;29(7):441-445
OBJECTIVETo investigate the expression level of preferentially expressed antigen of melanoma (PRAME) mRNA in newly diagnosed acute myeloid leukemia (AML) patients and evaluate its usefulness for detecting minimal residual disease (MRD).
METHODSPRAME mRNA levels were detected in bone marrow samples from 142 newly diagnosed AML patients (72 of them didn't express any specific fusion gene) by TaqMan based real-time quantitative PCR methods, and were serially monitored in 60 bone marrow samples from 9 follow-up patients (2 of them without specific fusion gene), including 3 in continuous complete remission, 6 in hematological relapse. Bone marrow samples from 22 bone marrow donors (NBM) were served as normal controls. Samples from 7 AML1-ETO (+) M2 patients were detected for AML1-ETO mRNA simultaneously. abl was selected as control gene, PRAME and AML1-ETO mRNA levels were expressed by their copies/abl copies in percentage.
RESULTSAll NBM samples expressed PRAME mRNA and the upper limit was 0.28%. For all newly diagnosed AML patients, median PRAME mRNA level was 3.97% (0.00%-714.97%), 76.8% of them was higher than 0.28%, 54.9% had over 1-log increasing and 26.1% had over 2-log increasing. For patients without specific fusion gene, median PRAME mRNA level was 0.60% (0.00%-408.72%), 56.3% of them was over 0.28%, 32.4% and 11.3% had over 1-log and 2-log increasing, respectively. There was a significant difference in PRAME mRNA levels between subtypes of AML patients (P<0.01). AML1-ETO (+) M2 patients expressed the highest levels (all P<0.01), followed by acute promyelocytic leukemia patients with S type PML-RAR alpha fusion gene. PRAME and AML1-ETO mRNA levels of follow up patients displayed similar kinetic patterns, and correlated well in 43 follow up samples (r=0.88, P<0.01). PRAME mRNA levels in 3 hematological relapsed patients increased above 0.28% 1-4 months ahead relapse, and in other 3 relapsed patients the levels never decreased to normal range even in remission.
CONCLUSIONSPRAME mRNA could be used to monitor MRD for AML patients with higher than normal levels, and it increases over or persistently higher than normal range predicts hematological relapse.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm ; genetics ; metabolism ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute ; diagnosis ; metabolism ; Male ; Middle Aged ; Neoplasm, Residual ; diagnosis ; metabolism ; RNA, Messenger ; genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Young Adult
10.Reduced expression of PDLIM4 gene correlates with good prognosis in acute myeloid leukemia.
Yun LI ; Jun QIAN ; Jiang LIN ; Wei QIAN ; Jing YANG ; Hai-Yan CHAI ; Cui-Zhu WANG ; Zhao-Qun DENG ; Dong-Ming YAO ; Qin CHEN ; Ji-Chun MA
Journal of Experimental Hematology 2013;21(5):1111-1115
This study was aimed to investigate the expression pattern of gene PDLIM4 (PDZ and LIM domain 4) and analyze its clinical correlation with the patients suffered from acute myeloid leukemia (AML). The expression pattern of PDLIM4 in AML was detected by using EvaGreen real-time quantitative PCR (RQ-PCR). The results showed that the PDLIM4 transcript significantly decreased in 94 AML patients, compared with 21 controls (P < 0.01). The decrease of PDLIM4 transcript was found in 42 (45%) AML patients. PDLIM4 low-expression occurred among the subtypes of M1/M2/M3 more frequently than that in M4/M5/M6 (56% vs 20%, P < 0.01). AML patients with PDLIM4 low-expression had an overall survival (OS) higher than that in AML patients without PDLIM4 low-expression (P < 0.05). Analysis with receiver operating characteristic curve (ROC) displayed that PDLIM4 expression possesses the diagnostic value to differentiate AML from controls, with ROC curve area of 0.865 (95% CI: 0.801-0.930). It is concluded that reduced PDLIM4 expression is a common and favorable event for the good prognosis in AML, and can be used as a potential diagnostic biomarker of cancer.
Adolescent
;
Adult
;
Aged
;
Biomarkers, Tumor
;
metabolism
;
Case-Control Studies
;
DNA-Binding Proteins
;
genetics
;
metabolism
;
Female
;
Humans
;
LIM Domain Proteins
;
genetics
;
metabolism
;
Leukemia, Myeloid, Acute
;
diagnosis
;
genetics
;
metabolism
;
Male
;
Middle Aged
;
Prognosis
;
Young Adult